During the last session, Novavax Inc. (NASDAQ:NVAX)’s traded shares were 6.63 million, with the beta value of the company hitting 1.57. At the end of the trading day, the stock’s price was $47.98, reflecting an intraday gain of 11.79% or $5.06. The 52-week high for the NVAX share is $277.80, that puts it down -478.99 from that peak though still a striking 13.01% gain since the share price plummeted to a 52-week low of $41.74. The company’s market capitalization is $3.84B, and the average intraday trading volume over the past 10 days was 7.13 million shares, and the average trade volume was 4.54 million shares over the past three months.
Novavax Inc. (NVAX) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.30. NVAX has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.4.
Novavax Inc. (NASDAQ:NVAX) trade information
Novavax Inc. (NVAX) registered a 11.79% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 11.79% in intraday trading to $47.98 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -18.21%, and it has moved by -17.42% in 30 days. Based on these gigs, the overall price performance for the year is -60.35%. The short interest in Novavax Inc. (NASDAQ:NVAX) is 9.47 million shares and it means that shorts have 1.45 day(s) to cover.
The consensus price target of analysts on Wall Street is $174.83, which implies an increase of 72.56% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $132.00 and $207.00 respectively. As a result, NVAX is trading at a discount of -331.43% off the target high and -175.11% off the low.
Novavax Inc. (NVAX) estimates and forecasts
Statistics show that Novavax Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Novavax Inc. (NVAX) shares have gone down -70.78% during the last six months, with a year-to-date growth rate more than the industry average at 204.18% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 85.20% this quarter and then jump 250.20% in the quarter after that. In the rating firms’ projections, revenue will increase 189.70% compared to the previous financial year.
Revenue for the current quarter is expected to be $453.5 million as predicted by 5 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $778.6 million by the end of Mar 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $279.66 million and $233.9 million respectively. In this case, analysts expect current quarter sales to grow by 62.20% and then jump by 232.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -2.50%. While earnings are projected to return -222.50% in 2022, the next five years will return 0.00% per annum.
Novavax Inc. is due to release its next quarterly earnings between February 28 and March 04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Novavax Inc. (NASDAQ:NVAX)’s Major holders
Novavax Inc. insiders own 0.57% of total outstanding shares while institutional holders control 44.58%, with the float percentage being 44.84%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 628 institutions own stock in it. As of Dec 30, 2021, the company held over 6.9 million shares (or 9.04% of all shares), a total value of $986.75 million in shares.
The next largest institutional holding, with 4.4 million shares, is of Blackrock Inc.’s that is approximately 5.76% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $628.82 million.
Also, the Mutual Funds coming in first place with the largest holdings of Novavax Inc. (NVAX) shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 2.15 million shares. This amounts to just over 2.82 percent of the company’s overall shares, with a $307.43 million market value. The same data shows that the other fund manager holds slightly less at 1.9 million, or about 2.50% of the stock, which is worth about $272.49 million.